Warmuth Markus's most recent trade in Monte Rosa Therapeutics Inc was a trade of 5,467 Common Stock done at an average price of $18.9 . Disclosure was reported to the exchange on May 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.92 per share. | 01 May 2026 | 5,467 | 600,004 | - | 18.9 | 103,447 | Common Stock |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 17.64 per share. | 14 Apr 2026 | 8,000 | 605,471 | - | 17.6 | 141,125 | Common Stock |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 17.92 per share. | 02 Mar 2026 | 5,466 | 613,471 | - | 17.9 | 97,974 | Common Stock |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 23.24 per share. | 07 Jan 2026 | 3,707 | 620,696 | - | 23.2 | 86,159 | Common Stock |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 23.88 per share. | 07 Jan 2026 | 1,450 | 619,246 | - | 23.9 | 34,620 | Common Stock |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 24.57 per share. | 07 Jan 2026 | 309 | 618,937 | - | 24.6 | 7,593 | Common Stock |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 406,000 | 406,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 634,538 | - | - | Common Stock | |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 15.17 per share. | 02 Jan 2026 | 10,135 | 624,403 | - | 15.2 | 153,748 | Common Stock |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 575,000 | 575,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 128,000 | 544,538 | - | - | Common Stock | |
| Monte Rosa Therapeutics Inc | Warmuth Markus | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 346,000 | 346,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 472,000 | 472,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 315,600 | 315,600 | - | - | Stock Option (Right to Buy) |